Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25204166 | 0.77 | CYP2D6 (0.46) | TDP1KCNH2ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL13885785 | 0.77 | KMT2A (0.41) | TDP1KCNH2ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL1960773 | 0.77 | — | — | |
| SCHEMBL8391864 | 0.73 | TDP1 (0.48) | TDP1ALDH1A1KMT2AMEN1 | |
| SCHEMBL12639970 | 0.72 | GPR119 (0.35) | KCNH2ALDH1A1CYP3A4MAPK1CYP2C19 | |
| SCHEMBL2282942 | 0.71 | EPHX1 (0.50) | TDP1ALDH1A1KMT2AMEN1 | |
| SCHEMBL25833953 | 0.71 | EPHX1 (0.50) | TDP1ALDH1A1KMT2AMEN1 | |
| SCHEMBL1605066 | 0.71 | EPHX1 (0.50) | TDP1ALDH1A1KMT2AMEN1 | |
| SCHEMBL2150521 | 0.70 | KDM4E (0.41) | ALDH1A1MAPK1 | |
| SCHEMBL31501258 | 0.69 | KCNH2 (0.38) | KCNH2ALDH1A1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010057-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010057-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010057-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| EP-2016063-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE | Chroma Therapeutics Limited (GB) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007129048-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129048-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010057-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE | NR4A3, NR2E1, NR2E3 | TDP1 2389/4885KCNH2 2814/4885ALDH1A1 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.